We therefore do not anticipate that “triple negative” or “SCLC-I” tumors identified in recent, thoroughly histopathologically characterized SCLC cohorts are likely to represent SMARCA4-UT. This evidence concerns the gene SMARCA4 and small cell lung carcinoma.